Tafamidis Alternatives Compared
| Tafamidis | Wainua (eplontersen) | Onpattro (patisiran) |
|
|---|
| Tafamidis | Wainua (eplontersen) | Onpattro (patisiran) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Transthyretin-Related Amyloidosis, Hereditary Amyloidosis. Tafamidis may also be used for purposes not listed in this medication guide. View more |
Prescription only
Prescribed for Transthyretin-Related Amyloidosis. Wainua may also be used for purposes not listed in this medication guide. |
Prescription only
Onpattro (patisiran) contains small lipid nanoparticles that contain small interfering RNAs that break down deposits of transthyretin - a protein that is increased by a rare condition called... View more |
||||||||||||||||
| More about Tafamidis | More about Wainua (eplontersen) | More about Onpattro (patisiran) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Tafamidis has an average rating of 7.6 out of 10 from a total of 14 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 0% reported a negative effect. |
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Tafamidis side effects |
View all Wainua side effects |
View all Onpattro side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Wainua prices |
View all Onpattro prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Vyndamax, Vyndaqel |
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
59 hours |
504 hours |
76.8 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 33 drugs are known to interact with Tafamidis:
|
No known drug interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known drug interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
May 03, 2019 |
N/A |
August 10, 2018 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Vyndamax
Vyndamax may be given to reduce death or hospitalization caused by heart problems in adults with ...
Tegsedi
Tegsedi (inotersen) is an RNA-targeting treatment that may be used to reduce the symptoms of ...
Vyndaqel
Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer that may be given to reduce death or ...
Onpattro
Onpattro is used to treat polyneuropathy in adults with hereditary transthyretin-mediated ...
Wainua
Wainua (eplontersen) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.